Icosapent Ethyl is a synthetic derivate of the omega-3 fatty acid eicosapentaenoic acid (EPA), prescribed as an adjunct to diet to reduce hypertriglyceridemia in adults.

[Huston J, et al. Am J Cardiovasc Drugs. 2023;2b] The FDA initially approved icosapent ethyl (Vascepa, Amarin) in 2012 [Vascepa prescribing information;1a] for the treatment of ...

VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a ...

Icosapent ethyl hit its primary composite endpoint ... Amarin said in a statement that this is the first drug in the class to be recommended by NICE for cardiovascular risk reduction.

This allows the MHRA to mirror decisions taken by the European Commission for drugs filed through the European Medicines Agency’s centralised procedure. Icosapent ethyl has been identified as a ...

Vascepa (icosapent ethyl) is a brand-name prescription medication ... If a person has a Part D drug plan or drug coverage through Medicare Advantage, their plan may cover Vascepa as a treatment ...

In a regulatory filing on Tuesday, the Dublin, Ireland-based company said that the PBM would no longer cover Vascepa as its exclusive icosapent ethyl product in its commercial national formularies ...

an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition ...